RAC 2.92% $1.94 race oncology ltd

Ann: Breakthrough Zantrene Heart Protection Discovery, page-139

  1. 336 Posts.
    lightbulb Created with Sketch. 29
    Hi @RaceOncology what is your level of confidence, regarding the likelihood of the recent cardio protection results being replicated in human trials? I understand there is already trial data which strongly hints at this, ie I when used previously it has been shown to have a much lower percentage of heart-impacted patients. So the circumstantial evidence seems strong. Can you comment on this?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.